Compare CASS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | ERAS |
|---|---|---|
| Founded | 1906 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 439.7M |
| IPO Year | 1996 | 2021 |
| Metric | CASS | ERAS |
|---|---|---|
| Price | $42.94 | $3.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $45.50 | $3.50 |
| AVG Volume (30 Days) | 95.6K | ★ 1.9M |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 37.29 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $222,318,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | $21.30 | ★ N/A |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $36.08 | $1.01 |
| 52 Week High | $47.00 | $3.38 |
| Indicator | CASS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 65.36 | 65.86 |
| Support Level | $40.52 | $2.81 |
| Resistance Level | $43.68 | $3.38 |
| Average True Range (ATR) | 1.01 | 0.24 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 84.70 | 87.23 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.